Establishment of a quantitative assay of abnormal glycolipid expression in endometrial cells, and its diagnostic value for endometrial carcinoma

Yoichi Kobayashi, Katsumi Tsukazaki, Kaneyuki Kubushiro, Motoko Sakayori, Shiro Nozawa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We developed a new quantitative method for detecting abnormal glycolipid expression in endometrial cells using a monoclonal antibody (MSN-1) and analyzed the glycolipid antigen recognized by MSN-1 in 173 clinical endometrial cell samples (66 normal endometria, 39 endometrial hyperplasias, and 68 endometrial adenocarcinomas). The mean glycolipid antigen levels in normal endometrium, endometrial hyperplasia, and endometrial carcinoma were 0.42 ± 137, 2.13 ± 3.84, and 19.4 ± 25.8 (mean ± SD) units, respectively. If the cutoff rate of this assay was fixed at 1.8 units, the positivity rates for patients with normal endometrium, endometrial hyperplasia, and endometrial carcinoma were 6.1% (4/66). 28.2% (11/39), and 76.5% (52/68), respectively. In 35 endometrial carcinoma patients, endometrial smears were simultaneously performed, and there were 22 positive smears (62.9%). When the cytological diagnosis was combined with our assay, 943% (33/35) of the carcinomas were detected. Thus, this assay seems to be a supplementary diagnostic method for endometrial carcinoma.

Original languageEnglish
Pages (from-to)749-754
Number of pages6
JournalClinical Cancer Research
Volume2
Issue number4
Publication statusPublished - 1996 Apr

Fingerprint

Glycolipids
Endometrial Neoplasms
Endometrial Hyperplasia
Endometrium
Antigens
Adenocarcinoma
Monoclonal Antibodies
Carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Establishment of a quantitative assay of abnormal glycolipid expression in endometrial cells, and its diagnostic value for endometrial carcinoma. / Kobayashi, Yoichi; Tsukazaki, Katsumi; Kubushiro, Kaneyuki; Sakayori, Motoko; Nozawa, Shiro.

In: Clinical Cancer Research, Vol. 2, No. 4, 04.1996, p. 749-754.

Research output: Contribution to journalArticle

Kobayashi, Yoichi ; Tsukazaki, Katsumi ; Kubushiro, Kaneyuki ; Sakayori, Motoko ; Nozawa, Shiro. / Establishment of a quantitative assay of abnormal glycolipid expression in endometrial cells, and its diagnostic value for endometrial carcinoma. In: Clinical Cancer Research. 1996 ; Vol. 2, No. 4. pp. 749-754.
@article{065ebaef068a446e919f546760c0bc11,
title = "Establishment of a quantitative assay of abnormal glycolipid expression in endometrial cells, and its diagnostic value for endometrial carcinoma",
abstract = "We developed a new quantitative method for detecting abnormal glycolipid expression in endometrial cells using a monoclonal antibody (MSN-1) and analyzed the glycolipid antigen recognized by MSN-1 in 173 clinical endometrial cell samples (66 normal endometria, 39 endometrial hyperplasias, and 68 endometrial adenocarcinomas). The mean glycolipid antigen levels in normal endometrium, endometrial hyperplasia, and endometrial carcinoma were 0.42 ± 137, 2.13 ± 3.84, and 19.4 ± 25.8 (mean ± SD) units, respectively. If the cutoff rate of this assay was fixed at 1.8 units, the positivity rates for patients with normal endometrium, endometrial hyperplasia, and endometrial carcinoma were 6.1{\%} (4/66). 28.2{\%} (11/39), and 76.5{\%} (52/68), respectively. In 35 endometrial carcinoma patients, endometrial smears were simultaneously performed, and there were 22 positive smears (62.9{\%}). When the cytological diagnosis was combined with our assay, 943{\%} (33/35) of the carcinomas were detected. Thus, this assay seems to be a supplementary diagnostic method for endometrial carcinoma.",
author = "Yoichi Kobayashi and Katsumi Tsukazaki and Kaneyuki Kubushiro and Motoko Sakayori and Shiro Nozawa",
year = "1996",
month = "4",
language = "English",
volume = "2",
pages = "749--754",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Establishment of a quantitative assay of abnormal glycolipid expression in endometrial cells, and its diagnostic value for endometrial carcinoma

AU - Kobayashi, Yoichi

AU - Tsukazaki, Katsumi

AU - Kubushiro, Kaneyuki

AU - Sakayori, Motoko

AU - Nozawa, Shiro

PY - 1996/4

Y1 - 1996/4

N2 - We developed a new quantitative method for detecting abnormal glycolipid expression in endometrial cells using a monoclonal antibody (MSN-1) and analyzed the glycolipid antigen recognized by MSN-1 in 173 clinical endometrial cell samples (66 normal endometria, 39 endometrial hyperplasias, and 68 endometrial adenocarcinomas). The mean glycolipid antigen levels in normal endometrium, endometrial hyperplasia, and endometrial carcinoma were 0.42 ± 137, 2.13 ± 3.84, and 19.4 ± 25.8 (mean ± SD) units, respectively. If the cutoff rate of this assay was fixed at 1.8 units, the positivity rates for patients with normal endometrium, endometrial hyperplasia, and endometrial carcinoma were 6.1% (4/66). 28.2% (11/39), and 76.5% (52/68), respectively. In 35 endometrial carcinoma patients, endometrial smears were simultaneously performed, and there were 22 positive smears (62.9%). When the cytological diagnosis was combined with our assay, 943% (33/35) of the carcinomas were detected. Thus, this assay seems to be a supplementary diagnostic method for endometrial carcinoma.

AB - We developed a new quantitative method for detecting abnormal glycolipid expression in endometrial cells using a monoclonal antibody (MSN-1) and analyzed the glycolipid antigen recognized by MSN-1 in 173 clinical endometrial cell samples (66 normal endometria, 39 endometrial hyperplasias, and 68 endometrial adenocarcinomas). The mean glycolipid antigen levels in normal endometrium, endometrial hyperplasia, and endometrial carcinoma were 0.42 ± 137, 2.13 ± 3.84, and 19.4 ± 25.8 (mean ± SD) units, respectively. If the cutoff rate of this assay was fixed at 1.8 units, the positivity rates for patients with normal endometrium, endometrial hyperplasia, and endometrial carcinoma were 6.1% (4/66). 28.2% (11/39), and 76.5% (52/68), respectively. In 35 endometrial carcinoma patients, endometrial smears were simultaneously performed, and there were 22 positive smears (62.9%). When the cytological diagnosis was combined with our assay, 943% (33/35) of the carcinomas were detected. Thus, this assay seems to be a supplementary diagnostic method for endometrial carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0029999053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029999053&partnerID=8YFLogxK

M3 - Article

C2 - 9816226

AN - SCOPUS:0029999053

VL - 2

SP - 749

EP - 754

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 4

ER -